Hester Biosciences Limited

BSE: 524669 NSE: HESTERBIO
Hester Biosciences Limited - pharma in Mehsana, Gujarat, India. FY 2026 financials & compliance.
CIN L99999GJ1987PLC022333 Incorporated 29 April 1987 ROC Ahmedabad HQ Mehsana, Gujarat, India
Active Listed - NSE: HESTERBIO · BSE: 524669 Public Limited Company pharma
Data last updated
Market Cap
₹2,048 Cr
HESTERBIO · NSE
Share Price
₹2,371.40
-1.49% today
Revenue
₹333 Cr
FY 2025-26 · +6.9% YoY
EBITDA
₹86.66 Cr
Margin 26.1%
Net Profit
₹53.57 Cr
FY 2025-26 · +92.6% YoY
P/E (TTM)
37.1x
P/B 5.5x
ROE
17.0%
ROCE 14.6%
Debt / Equity
0.60
Interest cover 16.1x

About Hester Biosciences Limited

Data last updated:

Hester Biosciences Limited is a public limited company based in Mehsana, Gujarat, India. It operates in the animal pharmaceuticals and healthcare segment of the pharmaceuticals sector. It was incorporated on 29 April 1987 and has been in existence for over 39 years.

Its director Rajiv Gandhi and family are #1,608 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L99999GJ1987PLC022333. Its GSTIN is 24AAACH2863B1Z4 (Gujarat). The company holds 10 GST registrations, of which 9 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524669 and NSE: HESTERBIO.

The company has an authorised share capital of ₹11.2 Cr and a paid-up capital of ₹8.51 Cr. It was formerly known as Hester Pharmaceuticals Limited and Hester Pharmaceuticals Private Limited. It is led by directors including Rajiv Gandhi (Managing Director) and Priya Rajiv Gandhi (Whole-Time Director).

Its last annual general meeting (AGM) was held on 13 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mehsana, Gujarat.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹332.6 Cr, a growth of 6.9% compared to the previous year. For the same year it recorded a net profit of ₹53.57 Cr (net margin 16.1%) and EBITDA of ₹86.66 Cr (EBITDA margin 26.1%). The net worth stands at ₹360.24 Cr (up 14.6% YoY). Total assets are valued at ₹615.17 Cr (up 3.1% YoY).

The company has about 695 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Hester Biosciences. As per MCA filings, the company has open charges of ₹202.05 Cr and satisfied charges of ₹90.09 Cr on record. Court records list 30 cases involving the company, including 17 filed by the company and 13 filed against it; 10 cases are pending. The company has 12 deals on record (12 market trades); the latest was in March 2017. The company has 8 MSME Form 1 returns on record between 2019 and 2024, listing 100 overdue payments to 58 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website hester.in.

Company details

CIN L99999GJ1987PLC022333
Registration Number 022333
Incorporation Date 29 April 1987
ROC Ahmedabad
Listing Status Listed - Listed on NSE (HESTERBIO); Listed on BSE (524669)
Company Status Active
Date of Last AGM 13 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Hester Biosciences has undergone 2 name changes throughout its history. The company was previously known as Hester Pharmaceuticals Limited, and Hester Pharmaceuticals Private Limited. The current legal name is Hester Biosciences Limited.

Company NameStatus
Hester Biosciences LimitedCurrent
Hester Pharmaceuticals LimitedPrevious
Hester Pharmaceuticals Private LimitedPrevious

CIN history

Hester Biosciences has one previous CIN (Corporate Identification Number): L99999GJ1994PTC022333. The current CIN is L99999GJ1987PLC022333, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L99999GJ1987PLC022333Current
L99999GJ1994PTC022333Previous
Key People
Rajiv Gandhi Managing Director Priya Rajiv Gandhi Whole-Time Director Sanjiv Dinesh Gandhi Director

Recognitions & Rankings of Hester Biosciences

India's Richest People 2026 edition · 1 director · Source: Hurun India

Contact details

Hester Biosciences Limited's registered office is in Mehsana, Gujarat. Its website is hester.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    hester.in
  • Social Media
  • Registered Address
    Village Meda – Adraj, Taluka Kadi, Mehsana, Gujarat, India – 384441
  • Industry
    Pharma, Animal Pharmaceuticals & Healthcare

To see the full contact details of Hester Biosciences Limited, buy the company report.

Comprehensive company report
Hester Biosciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Hester Biosciences operates one associated brand: Hester Biosciences. Each brand links to its own profile.

BrandDescriptionWebsite
Hester Biosciences
Manufacturer of animal vaccines and healthcare productshester.in

Business activity

The main business activities of Hester Biosciences are manufacturing and trade. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations and wholesale trading. 2 activity segments are registered with the MCA.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Hester Biosciences Limited, buy the company report.

Financials of Hester Biosciences Limited

FY 2025-26 filings available

Hester Biosciences Limited reported revenue of ₹332.6 Cr (up 6.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹333 Cr
+6.9% YoY
EBITDA
₹86.66 Cr
+42.0% YoY
Profit After Tax
₹53.57 Cr
+92.6% YoY
Net Worth
₹360 Cr
+14.6% YoY
Total Assets
₹615 Cr
+3.1% YoY
Total Debt
₹195 Cr
-8.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue333311305266235214183
Revenue growth+6.9%+2.2%+14.5%+13.2%+9.7%+17.0%-
EBITDA86.6661.0453.6550.6060.0065.3355.40
EBITDA margin+26.1%+19.6%+17.6%+19.0%+25.5%+30.5%+30.2%
Profit before tax75.8439.5631.9540.1453.5250.1041.33
Net profit53.5727.8118.8626.6039.2636.6128.80
Net profit margin+16.1%+8.9%+6.2%+10.0%+16.7%+17.1%+15.7%
EPS (₹)65.4032.3122.2031.3046.2240.4734.29
Balance sheet
Total assets615597606598517364339
Net worth360314292280260228201
Total debt195213244274228105121
Cash & bank6.547.2215.3014.8225.2021.2723.53
Net working capital155144166163156122120
Cash flow
Cash from operations64.1464.5148.1823.608.7158.0536.77
Cash from investing(18.17)(19.51)(22.45)(76.95)(117)(42.10)(72.63)
Cash from financing(48.79)(51.72)(26.09)41.76112(18.22)18.74
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue77.2410077.4270.9784.1181.9363.2283.69
Revenue growth (YoY)-8.2%+22.2%+22.5%-15.2%+2.2%---
Other income89.031.771.9811.883.37(5.64)8.782.80
EBITDA22.7734.3317.8011.7222.8219.195.0619.16
EBITDA margin+29.5%+34.3%+23.0%+16.5%+27.1%+23.4%+8.0%+22.9%
Depreciation7.045.914.434.354.184.184.294.20
Interest3.085.101.822.211.815.62(3.81)5.89
Profit before tax10225.0913.5317.0420.203.7513.3611.87
Tax4.958.544.222.712.902.201.963.48
Net profit96.7316.559.3114.3317.301.5511.408.39
EPS (₹)113.7119.4510.9416.8520.331.8213.419.86
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue292286285254219208169
Revenue growth+2.0%+0.5%+12.3%+15.8%+5.2%+23.1%-
EBITDA72.4850.9447.3554.8760.5666.7352.72
EBITDA margin+24.8%+17.8%+16.6%+21.6%+27.6%+32.0%+31.1%
Profit before tax69.6941.7536.7443.9053.2554.8041.23
Net profit47.0232.1827.1432.3039.4243.6030.84
Net profit margin+16.1%+11.2%+9.5%+12.7%+18.0%+20.9%+18.2%
EPS (₹)61.2437.4331.9338.0246.4546.9036.70
Balance sheet
Total assets509497499483392254251
Net worth385339313292268238203
Total debt74.7510413416412215.9047.90
Cash & bank4.562.184.965.961.981.245.19
Net working capital151142161161140118105
Cash flow
Cash from operations50.9263.9742.8633.3615.9141.1025.82
Cash from investing(2.36)(19.04)(20.59)(71.96)(111)(3.72)(21.33)
Cash from financing(48.31)(46.35)(24.12)41.3894.96(41.33)(1.39)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue72.6693.7170.3564.5863.4976.6762.8373.50
Revenue growth (YoY)+14.4%+22.2%+12.0%-12.1%-13.6%---
Other income1.6811.181.041.480.951.061.301.35
Total expenses48.3162.2553.6452.7051.0862.9753.8158.77
EBITDA24.3531.4616.7111.8812.4113.709.0214.73
EBITDA margin+33.5%+33.6%+23.8%+18.4%+19.5%+17.9%+14.4%+20.0%
Depreciation4.923.682.212.202.162.032.242.19
Interest1.364.090.901.270.911.251.591.40
Profit before tax19.7534.8714.649.8910.2911.486.4912.49
Tax5.048.483.972.672.451.852.053.15

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 07 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue77.2410077.4270.9784.1181.9363.2283.69
Revenue growth (YoY)-8.2%+22.2%+22.5%-15.2%+2.2%---
Other income89.031.771.9811.883.37(5.64)8.782.80
EBITDA22.7734.3317.8011.7222.8219.195.0619.16
EBITDA margin+29.5%+34.3%+23.0%+16.5%+27.1%+23.4%+8.0%+22.9%
Depreciation7.045.914.434.354.184.184.294.20
Interest3.085.101.822.211.815.62(3.81)5.89
Profit before tax10225.0913.5317.0420.203.7513.3611.87
Tax4.958.544.222.712.902.201.963.48
Net profit96.7316.559.3114.3317.301.5511.408.39
EPS (₹)113.7119.4510.9416.8520.331.8213.419.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue333311305266235214183
Revenue growth+6.9%+2.2%+14.5%+13.2%+9.7%+17.0%-
Other income18.998.0215.2519.5614.164.686.37
Total expenses246250251215175149128
Employee cost62.6762.4264.1356.0245.3338.9240.65
EBITDA86.6661.0453.6550.6060.0065.3355.40
EBITDA margin+26.1%+19.6%+17.6%+19.0%+25.5%+30.5%+30.2%
Depreciation18.8816.8017.1720.7016.5813.3113.07
Interest10.9312.7019.789.324.066.607.37
Profit before tax75.8439.5631.9540.1453.5250.1041.33
Tax18.3510.7410.7912.1214.0115.4110.33
Net profit53.5727.8118.8626.6039.2636.6128.80
Net profit margin+16.1%+8.9%+6.2%+10.0%+16.7%+17.1%+15.7%
EPS (₹)65.4032.3122.2031.3046.2240.4734.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital8.518.518.518.518.518.518.51
Reserves & surplus352306283271251220193
Shareholders' funds (net worth)360314292280260228201
Minority interest7.5512.4011.088.827.417.655.42
Secured loans188208239268223105121
Unsecured loans6.545.485.346.005.600.000.00
Total debt195213244274228105121
Total liabilities615597606598517364339
Assets
Gross block585390382386348228226
Net block411233240259237133143
Capital work in progress9.3318317114981.9110974.15
Investments42.5834.0529.9325.3121.240.000.00
Inventories72.5370.3875.5884.8175.3862.2263.97
Sundry debtors95.3673.1878.6579.6355.2849.2158.44
Cash & bank balances6.547.2215.3014.8225.2021.2723.53
Loans & advances34.1344.4045.0848.3438.9028.8013.38
Total current assets209195215228195162159
Total current liabilities53.9550.7848.5265.0238.5539.6939.26
Net working capital155144166163156122120
Total assets615597606598517364339
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5.5912.3112.6724.7521.2723.5340.65
Net cash from operating activities64.1464.5148.1823.608.7158.0536.77
Net cash from investing activities(18.17)(19.51)(22.45)(76.95)(117)(42.10)(72.63)
Net cash from financing activities(48.79)(51.72)(26.09)41.76112(18.22)18.74
Net change in cash(2.82)(6.72)(0.36)(11.59)3.48(2.26)(17.12)
Closing cash6.547.2215.3014.8225.2021.2723.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.9%+2.2%+14.5%+13.2%+9.7%+17.0%-
EBITDA growth+42.0%+13.8%+6.0%-15.7%-8.2%+17.9%-
PBT growth+91.7%+23.8%-20.4%-25.0%+6.8%+21.2%-27.3%
Net income growth+92.6%+47.5%-29.1%-32.3%+7.2%+27.1%-
Revenue CAGR (3Y)+7.7%+9.8%+12.4%+13.2%+9.7%+16.4%+14.2%
EBITDA CAGR (3Y)+19.6%+0.6%-6.4%-3.0%-4.1%+11.4%+10.5%
Profitability & leverage
Net income margin+17.3%+9.3%+7.0%+10.5%+16.8%+16.2%+16.9%
Return on capital employed+14.6%+8.9%+8.7%+9.0%+13.3%+16.5%+16.2%
Return on net worth+17.0%+9.5%+7.4%+10.4%+16.2%+16.2%+16.4%
Debt / equity0.600.760.910.930.680.520.56
Long-term debt / equity0.350.540.660.670.520.370.36
Interest cover16.1328.7154.2231.179.3512.6917.41
Efficiency & per share
Fixed asset turnover0.680.810.790.730.820.940.83
Inventory turnover4.654.263.803.323.423.403.19
Debtors turnover3.954.103.853.944.503.984.01
EPS (₹)65.4032.3122.2031.3046.2240.4734.29
Dividend per share (₹)11.007.006.008.0010.0010.006.60
Book value per share (₹)423.46369.41343.00328.82305.61268.38236.36
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue72.6693.7170.3564.5863.4976.6762.8373.50
Revenue growth (YoY)+14.4%+22.2%+12.0%-12.1%-13.6%---
Other income1.6811.181.041.480.951.061.301.35
Total expenses48.3162.2553.6452.7051.0862.9753.8158.77
EBITDA24.3531.4616.7111.8812.4113.709.0214.73
EBITDA margin+33.5%+33.6%+23.8%+18.4%+19.5%+17.9%+14.4%+20.0%
Depreciation4.923.682.212.202.162.032.242.19
Interest1.364.090.901.270.911.251.591.40
Profit before tax19.7534.8714.649.8910.2911.486.4912.49
Tax5.048.483.972.672.451.852.053.15
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue292286285254219208169
Revenue growth+2.0%+0.5%+12.3%+15.8%+5.2%+23.1%-
Other income14.634.764.265.324.661.652.93
Total expenses220236238199159142117
Employee cost53.1754.7656.7247.9239.1233.4537.16
EBITDA72.4850.9447.3554.8760.5666.7352.72
EBITDA margin+24.8%+17.8%+16.6%+21.6%+27.6%+32.0%+31.1%
Depreciation10.258.589.789.799.509.639.39
Interest7.175.375.096.502.473.955.03
Profit before tax69.6941.7536.7443.9053.2554.8041.23
Tax17.599.929.5811.5913.7414.8910.01
Net profit47.0232.1827.1432.3039.4243.6030.84
Net profit margin+16.1%+11.2%+9.5%+12.7%+18.0%+20.9%+18.2%
EPS (₹)61.2437.4331.9338.0246.4546.9036.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital8.518.518.518.518.518.518.51
Reserves & surplus377331304284260229195
Shareholders' funds (net worth)385339313292268238203
Secured loans74.4710413416412215.9047.90
Unsecured loans0.280.000.000.000.000.000.00
Total debt74.7510413416412215.9047.90
Total liabilities509497499483392254251
Assets
Gross block402212204199171165166
Net block28810510310884.3186.6496.47
Capital work in progress9.3318317114981.913.720.87
Investments64.2864.6964.6964.6964.6943.8940.67
Inventories59.9858.5168.5379.2270.7357.0160.43
Sundry debtors92.0480.6085.7882.3656.9245.5544.76
Cash & bank balances4.562.184.965.961.981.245.19
Loans & advances33.1843.9645.1548.5136.8435.8012.80
Total current assets190185204216166140123
Total current liabilities39.0743.7443.2255.5426.1821.4317.77
Net working capital151142161161140118105
Total assets509497499483392254251
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.551.973.811.531.245.192.09
Net cash from operating activities50.9263.9742.8633.3615.9141.1025.82
Net cash from investing activities(2.36)(19.04)(20.59)(71.96)(111)(3.72)(21.33)
Net cash from financing activities(48.31)(46.35)(24.12)41.3894.96(41.33)(1.39)
Net change in cash0.25(1.42)(1.85)2.770.28(3.95)3.10
Closing cash4.562.184.965.961.981.245.19
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.0%+0.5%+12.3%+15.8%+5.2%+23.1%-
EBITDA growth+42.3%+7.6%-13.7%-9.4%-9.3%+26.6%-
PBT growth+66.9%+13.6%-16.3%-17.6%-2.8%+32.9%-31.0%
Net income growth+46.1%+18.6%-16.0%-18.1%-9.6%+41.4%-
Revenue CAGR (3Y)+4.8%+9.3%+11.0%+14.5%+8.6%+15.7%+11.2%
EBITDA CAGR (3Y)+9.7%-5.6%-10.8%+1.3%-3.7%+10.4%+8.7%
Profitability & leverage
Net income margin+17.8%+11.1%+9.5%+12.7%+18.0%+19.1%+18.4%
Return on capital employed+15.3%+9.5%+8.5%+11.5%+17.3%+23.3%+19.7%
Return on net worth+14.4%+9.8%+9.0%+11.5%+15.6%+18.1%+16.3%
Debt / equity0.250.360.490.510.270.140.23
Long-term debt / equity0.100.200.270.280.150.020.05
Interest cover11.5212.6813.5514.424.846.9211.61
Efficiency & per share
Fixed asset turnover0.951.381.421.371.311.261.03
Inventory turnover4.934.513.863.393.433.553.11
Debtors turnover3.383.443.393.654.284.624.38
EPS (₹)61.2437.4331.9338.0246.4546.9036.70
Dividend per share (₹)11.007.006.008.0010.0010.006.60
Book value per share (₹)452.78398.60367.59343.70315.54279.28238.72

To see the full year-wise statements and ratios of Hester Biosciences Limited, buy the company report.

Board of directors of Hester Biosciences Limited

Hester Biosciences has 9 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Sanjiv Dinesh Gandhi
Also directs: Biolink Healthcare Limited, Stroke India Help Association, Hester Diagnostics Private Limited
Director29 Apr 198739 Years 6 MonthsCurrent
Bhupendra Vithaldas Gandhi
Also directs: Heritage Money Market Services Private Limited
Director21 Apr 200521 Years 6 MonthsCurrent
Rajiv Gandhi
Also directs: Biolink Healthcare Limited, Hester Diagnostics Private Limited, Hester Coatings LLP and 5 more
Managing Director29 Apr 198739 Years 6 MonthsCurrent
Ashok Bhadakal Bhimarao
Also directs: Agroaccess Consulting LLP, Endurant Management Services LLP, Venkateshwara Bioproducts Private Limited
Director01 Apr 20206 Years 7 MonthsCurrent
Priya Rajiv Gandhi
Also directs: Texas Lifesciences Private Limited, Aerotrans Services Private Limited, Blue Ray Aviation Private Limited and 2 more
Whole-Time Director28 Oct 20215 Years 0 MonthsCurrent
Ameetkumar Hiranyakumar Desai
Also directs: Anubhuti Advisors LLP, Corona Remedies Limited, Ambuja Cements Limited and 5 more
Director28 Oct 20215 Years 0 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Auditor

Hester Biosciences Limited is audited by CHANDULAL M. SHAH & CO. for the financial year 2025.

Auditor firmFinancial yearFirm registration number
CHANDULAL M. SHAH & CO.FY 2025101698W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 53.70%, foreign institutional investors hold 0.30%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 46.00%.

Promoters: 53.70%FII (Foreign Institutional): 0.30%Retail & Others: 46.00%
Sep 2026
QUARTER
53.70% Promoters
0.30% FII (Foreign Institutional)
46.00% Retail & Others
Promoter holding - history
Now 53.70% · Sep 2026High 53.70% · Dec 2025Low 53.70% · Dec 2025
52%52.8%53.5%54.3%55%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 53.70%Mar 2026: 53.70%Jun 2026: 53.70%Sep 2026: 53.70%53.70%53.70%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters53.70%53.70%53.70%53.70%
Public46.30%46.30%46.30%46.30%

Charges & borrowings

Open charges
₹202.05 Cr
Satisfied charges
₹90.09 Cr
Breakdown by lending institutions
State Bank of India₹202.05 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
18 Dec 2021100522724State Bank of India₹91.08 CrOpen
28 Dec 201310473280State Bank of India₹110.97 CrOpen
15 Apr 2020100334582State Bank of India₹5 CrSatisfied
16 Oct 2019100305133Hdfc Bank Limited₹37.7 LakhSatisfied
26 Jul 2019100280285Axis Bank Limited₹55.27 LakhSatisfied

To see the full charge records of Hester Biosciences Limited, buy the company report.

Total charge records: 30 View all charges

Deals & funding

Hester Biosciences Limited has 12 deals on record (12 market trades); the latest was in March 2017.

Total deals
12
Market trades
12

Deals on record (5 of 12)

WhenDealAmountParties
Mar 2017Market trade₹13.18 CrBuyer: an individual
Seller: Hester Coatings Private Limited
May 2012Market trade₹87.6 LakhBuyer: N K Proteins Private Limited
Seller: an individual
Dec 2007Market trade₹81.7 LakhSeller: Kankaria Brothers Pvt Ltd
Dec 2007Market trade₹2.48 CrBuyer: Shardul Securities Limited
Sep 2007Market trade₹1.38 CrBuyer: Kankaria Brothers Pvt Ltd

To see the full deal history of Hester Biosciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Hester Biosciences Limited was last rated by Care on 07 Feb 2023.

Rating agencyRated onRating
Care07 Feb 2023

To see the full credit ratings and regulatory alerts of Hester Biosciences Limited, buy the company report.

MSME payment delays

Hester Biosciences Limited has 8 MSME Form 1 returns on record between 2019 and 2024, listing 100 overdue payments to 58 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 58)

SupplierAmount dueDue sinceReported on
an individual supplier
Maridi Bio Industries Private Limited
an individual supplier
Naresh J. Patel & Co.
an individual supplier

To see the full MSME payment records of Hester Biosciences Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Hester Biosciences has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Texas Lifesciences Private LimitedU24304GJ2017PTC097758

To see the full group structure of Hester Biosciences Limited, buy the company report.

Employees & EPFO

Hester Biosciences Limited has a workforce of 695 employees on its EPFO records as of Sep 23, 2025, across 1 active EPFO establishment.

Employee count
695
Active EPFO establishments
1
Employee growth
1.31%

GST

Hester Biosciences has 10 GST registrations: 9 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
10
Active
9
Cancelled / inactive
1
GSTINStateStatusRegistered on
24AAACH2863B1Z4GujaratActive01 Jul 2017
24AAACH2863B2Z3GujaratActive01 Jun 2022
06AAACH2863B1Z2HaryanaActive01 Jul 2017
27AAACH2863B1ZYMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Hester Biosciences Limited, buy the company report.

Recent activity

Hester Biosciences Limited has 36 board changes on record since 1987: 23 appointments and 13 cessations. The latest: Anil Jain was appointed as Director on 26 Jun 2023.

Filing
Hester Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
AGM
Hester Biosciences Limited last Annual general meeting of members was held on 13 Aug 2025 as per latest MCA records.
Charges
A charge registered on 26 Jul 2019 via Charge ID 100280285 with Axis Bank Limited was fully satisfied on 11 Jul 2024.
Appointed
Anil Jain was appointed as Director.
Appointed
Jatin Yagneshbhai Trivedi was appointed as Director.
Ceased
Amit Priyatam Shukla ceased to be Director.
Ceased
Naman Madhav Patel ceased to be Director.
Charges
A charge with State Bank Of India of Rs. 110.97 Cr registered on 28 Dec 2013 with Charge ID 10473280 was modified on 29 Mar 2023.
Charges
A charge with State Bank Of India amounted to Rs. 91.08 Cr with Charge ID 100522724 was registered on 18 Dec 2021.
Appointed
Ameetkumar Hiranyakumar Desai was appointed as Director.
Appointed
Priya Rajiv Gandhi was appointed as Whole-Time Director.
Charges
A charge registered on 16 Oct 2019 via Charge ID 100305133 with Hdfc Bank Limited was fully satisfied on 06 Mar 2021.

92 earlier events are in the company report.

News

HESTERBIO: Q2 CONS NET PROFIT 204M RUPEES VS 145M (YOY)
05 Nov 2026 · Exchange Update
HESTERBIO: Q2 REVENUE 979M RUPEES VS 710M (YOY)
05 Nov 2026 · Exchange Update
HESTERBIO: Q2 EBITDA 327M RUPEES VS 117M (YOY); Q2 EBITDA MARGIN 33.4% VS 16.48% (YOY)
05 Nov 2026 · Exchange Update
Hester Biosciences: Co Approves Investment Up To Rs. 10.50 Million In Slyce Agri World LLP For Renewable Energy; This Will Be 26% Of LLP's Total Fixed Capital.
06 Oct 2026 · Exchange Update

Frequently asked questions

Hester Biosciences is an active public limited company based in Mehsana, Gujarat, India. The company works in animal pharmaceuticals and healthcare, within the pharma industry. It was incorporated on 29 April 1987 (39+ years old) and is registered under CIN L99999GJ1987PLC022333. Listed on BSE: 524669 and NSE: HESTERBIO.

Hester Biosciences reported revenue of ₹332.6 Cr for FY 2025-26 (up 6.9% YoY) based on consolidated financials.

Hester Biosciences has 9 current directors:

The latest financial statements of Hester Biosciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 13 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Hester Biosciences is 24AAACH2863B1Z4, registered in Gujarat. The company has 10 GST registrations in all, of which 9 are active and 1 is cancelled or inactive. Other active GSTINs include 24AAACH2863B2Z3 (Gujarat), 06AAACH2863B1Z2 (Haryana), 27AAACH2863B1ZY (Maharashtra).

The CIN (Corporate Identification Number) of Hester Biosciences is L99999GJ1987PLC022333. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Hester Biosciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 524669) and NSE (symbol: HESTERBIO).

Hester Biosciences has 30 court cases on record: 17 filed by the company and 13 filed against it. 10 are pending. Most are in the district courts.

Hester Biosciences was incorporated on 29 April 1987, making it 39+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Hester Biosciences has 12 deals on record (12 market trades); the latest was in March 2017.

Anil Jain was appointed as Director on 26 Jun 2023. Jatin Yagneshbhai Trivedi was appointed as Director on 26 Jun 2023. Amit Priyatam Shukla ceased to be Director on 01 Apr 2023. Hester Biosciences has 36 board changes on record in total.